146741-05-1

Basic information

• Product Name: 2(1H)-Quinoxalinone,7-fluoro-3,4-dihydro-3-methyl-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,7-fluoro-3,4-dihydro-3-methyl-(9CI);7-FLUORO-3-METHYL-3,4-DIHYDROQUINOXALIN-2(1H)-ONE
• CAS NO: 146741-05-1
• Molecular Formula: C9 H9 F N2 O
• Molecular Weight: 180.18
• Product Categories: PIPERIDINE
• Mol File: 146741-05-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 341.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.209±0.06 g/cm3(Predicted)
• PKA: 13.02±0.40(Predicted)
• CAS DataBase Reference: 2(1H)-Quinoxalinone,7-fluoro-3,4-dihydro-3-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,7-fluoro-3,4-dihydro-3-methyl-(9CI)(146741-05-1)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,7-fluoro-3,4-dihydro-3-methyl-(9CI)(146741-05-1)

Safety Data

• Hazardous Substances Data: 146741-05-1(Hazardous Substances Data)

Usage

Structure

A quinoxalinone derivative with a fluorine atom and a methyl group

Potential pharmaceutical applications

Due to its structural features and functional groups, it could be suitable for interactions with biological targets

Interest for further research and development

In the field of medicinal chemistry

Upstream product

• 311346-77-7 7-fluoro-3-methyl-1H-quinoxalin-2-one 

Relevant articles and documents

Versatile (Pentamethylcyclopentadienyl)rhodium-2,2′-Bipyridine (Cp?Rh-bpy) Catalyst for Transfer Hydrogenation of N-Heterocycles in Water

An investigation employing the catalytic system consisting of (pentamethylcyclopentadienyl)rhodium dichloride dimer [Cp?RhCl2]2 and 2,2′-bipyridine (bpy) for transfer hydrogenation of a variety of quinoxalines, quinoxalinones, quinolines and indoles under aqueous conditions with formate as the hydrogen source is reported. This approach provides various tetrahydroquinoxalines, dihydroquinoxalinones, tetrahydroquinolines and indolines in good to excellent yields. The activity of the catalyst towards quinoxalines and quinoxalinones is excellent, with a substrate to catalyst ratio (S/C) of 10000 being feasible. The choice of ligand is critical to the catalysis, and the aqueous phase reduction is shown to be highly pH-dependent, with acidic pH values needed for optimal reduction. The catalyst is easy to access, and the reaction is operationally simple without requiring an inert atmosphere.

Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.